DE68919537D1 - Aromatische Steroide als 5-alpha-Reduktase-Inhibitoren. - Google Patents

Aromatische Steroide als 5-alpha-Reduktase-Inhibitoren.

Info

Publication number
DE68919537D1
DE68919537D1 DE68919537T DE68919537T DE68919537D1 DE 68919537 D1 DE68919537 D1 DE 68919537D1 DE 68919537 T DE68919537 T DE 68919537T DE 68919537 T DE68919537 T DE 68919537T DE 68919537 D1 DE68919537 D1 DE 68919537D1
Authority
DE
Germany
Prior art keywords
alpha
beta
reductase inhibitors
alpha reductase
aromatic steroids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68919537T
Other languages
English (en)
Other versions
DE68919537T2 (de
Inventor
Dennis Alan Holt
Mark Alan Levy
Brian Walter Metcalf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of DE68919537D1 publication Critical patent/DE68919537D1/de
Application granted granted Critical
Publication of DE68919537T2 publication Critical patent/DE68919537T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0095—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 carbon in position 21 is part of carboxylic group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
DE68919537T 1988-05-25 1989-05-24 Aromatische Steroide als 5-alpha-Reduktase-Inhibitoren. Expired - Fee Related DE68919537T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19853488A 1988-05-25 1988-05-25

Publications (2)

Publication Number Publication Date
DE68919537D1 true DE68919537D1 (de) 1995-01-12
DE68919537T2 DE68919537T2 (de) 1995-05-11

Family

ID=22733779

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68919537T Expired - Fee Related DE68919537T2 (de) 1988-05-25 1989-05-24 Aromatische Steroide als 5-alpha-Reduktase-Inhibitoren.

Country Status (16)

Country Link
EP (1) EP0343954B1 (de)
JP (1) JP2675418B2 (de)
AT (1) ATE114665T1 (de)
AU (1) AU627466B2 (de)
CA (1) CA1331457C (de)
DE (1) DE68919537T2 (de)
DK (2) DK168295B1 (de)
ES (1) ES2065378T3 (de)
GR (1) GR3015135T3 (de)
HK (1) HK1006461A1 (de)
IE (1) IE68858B1 (de)
IL (1) IL91968A (de)
NO (1) NO174964C (de)
PT (1) PT90656B (de)
WO (1) WO1989011282A1 (de)
ZA (1) ZA893971B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
SK129294A3 (en) * 1992-04-30 1995-07-11 Smithkline Beecham Corp 17-alpha and 17-beta-substituted estra-1,3,5(10)-triene-3- -carboxylic acid
ES2148229T3 (es) * 1992-05-20 2000-10-16 Merck & Co Inc Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
RU94046044A (ru) * 1992-05-20 1996-10-10 Мерк Энд Ко. Новые 7 бета -замещенные 4-аза- 5 альфа -холестан-оны в качестве ингибиторов 5 альфа -редуктазы, фармацевтическая композиция на их основе, способ ее получения
JPH07508035A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ４−アザステロイド５α−レダクターゼ阻害剤
ATE183193T1 (de) * 1992-05-20 1999-08-15 Merck & Co Inc 17-amino-substituierte 4-azasteroide als 5-alpha- reductase inhibitoren
EP0649306B1 (de) * 1992-05-20 2001-01-10 Merck & Co. Inc. Ester derivate von 4-aza-steroiden
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5641765A (en) * 1992-11-18 1997-06-24 Smithkline Beecham Corporation 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase
US5683995A (en) * 1992-11-18 1997-11-04 Smithkline Beecham Corporation 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
AU6413594A (en) * 1993-03-24 1994-10-11 Merck & Co., Inc. Substituted 3-phenanthridinone derivatives as 5alpha-reductase inhibitors
JP3325026B2 (ja) * 1993-06-28 2002-09-17 メルク エンド カンパニー インコーポレーテッド ４−アザ−プレグナン５α−レダクターゼアイソザイム１阻害剤
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5430157A (en) * 1993-12-13 1995-07-04 Eli Lilly And Company Reduced phenanthrenes
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1107664B (de) * 1959-11-05 1961-05-31 Schering Ag Verfahren zur Herstellung neuer in 3-Stellung substituierter OEstratriene
US3622670A (en) * 1969-08-22 1971-11-23 American Home Prod Method of inducing ovulation
US4185101A (en) * 1977-08-11 1980-01-22 Schering Corporation 1,3,5(10),6,8-19-Nor-pregnapentaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4340602A (en) * 1978-10-18 1982-07-20 Wayne State University Compositions inhibiting estrogen sulfotransferase activity
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors

Also Published As

Publication number Publication date
HK1006461A1 (en) 1999-02-26
EP0343954B1 (de) 1994-11-30
DK169787B1 (da) 1995-02-27
ATE114665T1 (de) 1994-12-15
CA1331457C (en) 1994-08-16
DK168295B1 (da) 1994-03-07
DK279790A (da) 1990-11-23
PT90656A (pt) 1989-11-30
AU3748789A (en) 1989-12-12
PT90656B (pt) 1994-10-31
NO174964B (no) 1994-05-02
AU627466B2 (en) 1992-08-27
IL91968A (en) 1994-10-21
JP2675418B2 (ja) 1997-11-12
NO174964C (no) 1994-08-10
NO894065D0 (no) 1989-10-11
DK130393A (da) 1993-11-19
EP0343954A2 (de) 1989-11-29
JPH03504498A (ja) 1991-10-03
WO1989011282A1 (en) 1989-11-30
ZA893971B (en) 1990-05-30
IE891732L (en) 1989-11-25
DK130393D0 (da) 1993-11-19
ES2065378T3 (es) 1995-02-16
GR3015135T3 (en) 1995-05-31
IE68858B1 (en) 1996-07-24
EP0343954A3 (en) 1990-05-16
DE68919537T2 (de) 1995-05-11
NO894065L (no) 1991-04-12
DK279790D0 (da) 1990-11-23

Similar Documents

Publication Publication Date Title
ATE114665T1 (de) Aromatische steroide als 5-alpha-reduktase- inhibitoren.
ATE118505T1 (de) Phosphinsäure-derivate von aromatischen steroiden als 5-alpha reduktase-inhibitoren.
DE68920128T2 (de) Sulfonsäure-substituierte aromatische Steroide als 5-Alpha-Reduktase-Inhibitoren.
DE68917884T2 (de) Phosphinsäure-Derivate von Steroiden als 5-alpha-Reduktase-Inhibitoren.
DE69434063D1 (de) Substituierte Morpholinderivate und ihre Verwendung als therapeutische Mittel
FI103888B1 (fi) Analoginen menetelmä valmistaa terapeuttisesti aktiivista akridiinijohdannaista
ATE252576T1 (de) Heteroarylphenylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
DK0390114T3 (da) Undertrykkelse af syntese og udskillelse af parathyroidhormoner med vitamin D3 derivater
DE68917885T2 (de) Phosphonsäure-Derivate von Steroiden als Hemmstoffe der 5-alpha-Reduktase.
DK162646C (da) 3-(4-benzyl-piperazin-1-yl)-rifamycin sv- og s-forbindelser samt salte deraf, fremgangsmaade til fremstilling deraf og farmaceutiske sammensaetninger indeholdende disse forbindelser
DE68909107T2 (de) 4-Amino-3-acylchinolin-Derivate und ihre Verwendung als Inhibitoren der Magensekretion.
US4213978A (en) Anti-acne and anti-seborrhea prodrug derivatives of progesterone
ATE98253T1 (de) Synthese von 6-methylenandrosta-1,4-dien-3,17dion-derivate.
DK259387A (da) Steroide forbindelser, der er virksomme mod kraeft og obesitet
GB1514748A (en) Pharmaceutically active piperidine derivatives and preparation thereof
US3660385A (en) 2-(5-nitro-2-furfurylidene)-1-tetralones
NO924947L (no) Tetrazolderivater og legemidler
DE68903188T2 (de) Acylsulfonamid-derivate von alpha-carbocyclyltoluylsaeuren und ihre verwendung als leukotrienantagonisten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee